Who are Glyset's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zavesca, Glustat, Precose, sitagliptin and acarbose, Mulberry Leaf Extract, Acarbose Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/miglitol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Glyset — Competitive Intelligence Brief

Glyset (MIGLITOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alpha-Glucosidase Inhibitor. Area: Metabolic.

marketed alpha-Glucosidase Inhibitor Lysosomal alpha-glucosidase Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Glyset (MIGLITOL) — Pfizer. Glyset works by delaying the breakdown of carbohydrates in the gut, allowing less glucose to enter the bloodstream.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Glyset TARGET	MIGLITOL	Pfizer	marketed	alpha-Glucosidase Inhibitor	Lysosomal alpha-glucosidase	1996-01-01
Zavesca	MIGLUSTAT	AstraZeneca	marketed	Glucosylceramide Synthase Inhibitor [EPC]	Lysosomal alpha-glucosidase	2003-01-01
Glustat	VOGLIBOSE		marketed	voglibose	Lysosomal alpha-glucosidase	1994-01-01
Precose	ACARBOSE	Bayer	marketed	alpha-Glucosidase Inhibitor [EPC]	Sucrase-isomaltase, intestinal	1995-01-01
sitagliptin and acarbose	sitagliptin and acarbose	Nanjing First Hospital, Nanjing Medical University	marketed	DPP-4 inhibitor + alpha-glucosidase inhibitor combination	DPP-4 enzyme; alpha-glucosidase enzymes
Mulberry Leaf Extract	Mulberry Leaf Extract	University of Mississippi Medical Center	marketed	Alpha-glucosidase inhibitor	Alpha-glucosidase enzymes (intestinal disaccharidases)
Acarbose Tablets	Acarbose Tablets	University of Alabama at Birmingham	marketed	Alpha-glucosidase inhibitor	Alpha-glucosidase enzymes (including maltase, isomaltase, sucrase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-03-07 — Zavesca · 12419937 · Method of Use · US
2033-03-07 — Zavesca · 11278599 · Method of Use · US
2033-03-07 — Zavesca · 10512677 · Method of Use · US
2035-09-30 — Zavesca · 10961522 · Method of Use · US
2035-09-30 — Zavesca · 10208299 · Compound · US
2035-09-30 — Zavesca · 11753632 · Method of Use · US
2036-12-29 — Zavesca · 11278601 · Formulation · US
2036-12-29 — Zavesca · 12414985 · Method of Use · US
2037-08-12 — Zavesca · 10857212 · Method of Use · US
2038-09-16 — Zavesca · 12246062 · Method of Use · US

Sponsor landscape (alpha-Glucosidase Inhibitor class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glyset — Competitive Intelligence Brief. https://druglandscape.com/ci/miglitol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab